Hong Kong-listed Kangmei Pharmaceutical-B rose more than 20% in early trading.

Hong Kong Stock Tai Pharma-B Plate Initial Rise of more than 20%, the company's Phase I clinical MAD study has achieved positive preliminary results, and LAE102 has shown an inspiring trend of muscle growth and fat reduction.